By Duke Medicine News and Communications
DURHAM, N.C. -- African-American men are more likely to have
their prostate cancer return after treatment, but their disease
is no more aggressive when it does recur than that of their
white counterparts, according to a study led by Duke Prostate Center
researchers.
"Our study found that African-American men have a slightly
higher risk of what is known as PSA recurrence, which is a
blood test that indicates the presence of cancer based on the
levels of a certain biomarker known as prostate-specific
antigen," said Stephen Freedland, M.D., a urologist at Duke and
senior researcher on the study. "We were encouraged, however,
to see that their disease is not necessarily more aggressive
than that of white men, once it has recurred."
African-American men tend to have higher PSA levels at
initial diagnosis of prostate cancer, as well, despite being
diagnosed at younger ages. This suggests that there may be an
underlying genetic and biologic component that predisposes
African-American men to prostate disease, Freedland said,
highlighting the need for black men to have prostate screening
early and often.
The team's findings will be published in the November 15,
2007 print edition of the journal Cancer, but also appeared
early in the journal's September 17, 2007 online edition. The
study was funded by the U.S. Department of Defense, the
Prostate Cancer Research Program, the Department of Veterans
Affairs, the National Institutes of Health, the Georgia Cancer
Coalition and the American Urological Association
Foundation.
The researchers studied the medical records of 953 white and
659 black men who were treated for prostate cancer between 1988
and 2006 at five medical centers that make up the Shared Equal
Access Regional Cancer Hospital (SEARCH) database. All received
surgery, called radical prostatectomy, to treat their
cancer.
The team examined the relationship between race and the
amount of time that lapsed between surgery and recurrence, as
well as the level of PSA found in the blood of the patients,
Freedland said.
"We found that African-American men were 28 percent more
likely to experience a disease recurrence," said Robert
Hamilton, M.D., a urology resident at the University of Toronto
and former research fellow at Duke, and lead author on the
publication. "But when we compared the men who had experienced
recurrence, we found that the aggressiveness of the disease was
similar across the racial groups."
Although African-Americans may be more likely to see their
disease return after treatment, this study points to a trend
toward better screening and earlier detection among black men,
Freedland said.
"We did find that black men were diagnosed at younger ages
and had higher PSA levels, but the fact that their disease
seemed to be no more aggressive than that of their white
counterparts was encouraging," he said. "Earlier studies showed
that black men had more aggressive disease at the time of
diagnosis than other races, suggesting that their tumors were
being discovered at more advanced stages."
Screening has apparently improved, but "this study paves the
way for more work aimed at developing preventive and treatment
strategies directed at these genetic and biologic differences,"
Freedland said.
Other researchers involved in this study include William
Aronson of UCLA, Joseph Presti of Stanford, Martha Terris of
the Medical College of Georgia, Christopher Kane of the
University of California at San Francisco and Christopher
Amling of the University of Alabama-Birmingham. All authors
have joint appointments at affiliated Veterans Administration
hospitals.